ASCO 2025 | Influential breast cancer trials at ASCO 2025: DESTINY-Breast09
Christian Singer, MD, MPH, Medical University of Vienna, Vienna, Austria, gives an overview of the Phase III DESTINY-Breast09 trial (NCT04784715) of first-line trastuzumab deruxtecan (T-DXd) and pertuzumab in patients with HER2+ breast cancer. The combination therapy significantly improved progression-free survival, ushering in a new standard of care in this setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There were a couple of new trials that were presented. Certainly, DESTINY-Breast09 is remarkable and we see that there is a better long-term outcome in patients. We see that there is a better progression-free survival in patients who receive trastuzumab and deruxtecan in combination with pertuzumab when combined to the traditional standard, which is taxane and herceptin and pertuzumab...
There were a couple of new trials that were presented. Certainly, DESTINY-Breast09 is remarkable and we see that there is a better long-term outcome in patients. We see that there is a better progression-free survival in patients who receive trastuzumab and deruxtecan in combination with pertuzumab when combined to the traditional standard, which is taxane and herceptin and pertuzumab. I think that’s really a step forward and we can only congratulate the investigators who presented this.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria – AstraZeneca/MedImmune; Daiichi Sankyo Europe GmbH; Novartis
Consulting or Advisory Role – AstraZeneca/MedImmune; Daiichi-Sanyko; Gilead Sciences; Novartis; Sanofi/Aventis
Speakers’ Bureau – AstraZeneca/MedImmune; Novartis
Research Funding – Amgen; Amgen; AstraZeneca/MedImmune; Myriad Genetics; Novartis; Roche; Sanofi
Travel, Accommodations, Expenses – Daiichi-Sankyo; Gilead Sciences; Novartis; Roche
